Zhong-Yin Zhang, head of Purdue’s Department of Medicinal Chemistry and Molecular Pharmacology, developed highly potent and selective compounds for use in the treatment of tuberculosis.
Purdue University innovators have developed highly potent and selective compounds for use in the treatment of tuberculosis, which is one of the top 10 causes of death worldwide.
The Purdue researchers developed a series of small molecule inhibitors to target one of the proteins critical for the survival of TB in infected macrophages. Protein tyrosine phosphates B (mPTPB) is a virulence factor of TB to subvert the host immune responses.
The Purdue research is published in the Journal of Medicinal Chemistry.
“The death toll from TB is particularly high because of drug-resistant strains,” said Zhong-Yin Zhang, distinguished professor and head of Purdue’s Department of Medicinal Chemistry and Molecular Pharmacology and director of Purdue Institute for Drug Discovery. “These inhibitors are part of a promising new approach to developing TB therapeutic agents with novel targets and mechanisms of action to help save more lives.”
Current treatments for TB are mostly antibiotic-based solutions. A major problem is that a large number of patients fail to take the entire antibiotic regime, which can lead to drug-resistant strains.
“We developed a platform to target mPTPB for novel anti-TB agents that builds on technologies we pioneered to modulate abnormal protein tyrosine phosphatase activity for the treatment of diseases such as cancer, diabetes and autoimmune disorders,” Zhang said.
Zhang said these inhibitors’ properties also make them promising drug candidates. They possess lighter molecular weights, excellent metabolic stability and bioavailability to provide a starting point for further therapeutic development for use as TB treatments.
The innovators and OTC are looking for partners to continue developing their technology. For more information on licensing and other opportunities, contact Joseph Kasper of OTC at [email protected] and mention track code 2020-ZHAN-68995.
Original Article: New inhibitors may offer novel approach to treating deadly tuberculosis
More from: Purdue University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- COVID-19 pandemic slows progress against tuberculosis
The COVID-19 pandemic’s disruption to health services has seen an increase in tuberculosis deaths in Africa, the first such rise in more than a decade, while the decline in new cases slowed down, an ...
- Nigeria ranks sixth among tuberculosis high burden countries – IHVN
The Chief Executive Officer of the Institute of Human Virology Nigeria, Dr. Patrick Dakum has said Nigeria ranks sixth position among 30 tuberculosis high burden countries in the world. Dakum made ...
- Globalization and life lost due to tuberculosis: evidence from a multi-country study
Tuberculosis causes an increase in early mortality and thus has the potential to increase the number of years of life lost. Globalization directly or indirectly by affecting the factors that increase ...
- Africa: Covid-19 Pandemic Slows Progress Against Tuberculosis
Press Release - The COVID-19 pandemic's disruption to health services has seen an increase in tuberculosis deaths in Africa, the first such rise in more than a decade, while the decline in new cases ...
- This Woodhaven hospital tripled NYC’s ability to treat tuberculosis: Our Neighborhood, The Way it Was
Just over a century ago, the Franciscan Sisters of the Poor founded St. Anthony’s Hospital with the purpose of treating patients suffering from tuberculosis ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Small molecule inhibitors
- Lutris Pharma Expands Intellectual Property Portfolio Surrounding its Novel B-Raf inhibitors Including Lead Asset LUT014
Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side ...
- China Anlotinib Hydrochloride Market Research Report 2021: A Novel Small Molecule Multi-target Tyrosine Kinase Inhibitor that Effectively Inhibits Kin
The "Research Report on China's Anlotinib Hydrochloride Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering. Anlotinib hydrochloride is a novel small molecule multi-target ...
- Global Small Molecule Inhibitors for Cancer Therapy Market 2021 Key Trends, Sales Growth, Market Value-Chain and Forecast to 2027
Global Small Molecule Inhibitors for Cancer Therapy Market Growth (Status and Outlook) 2021-2027 delivers extensive as well as object-oriented market research which has been formulated with the nice ...
- Kinnate Biopharma - Exploring The RAF Inhibitor Landscape
Shares of Kinnate Biopharma Inc. (KNTE) are down over 50% from their all-time high of $48.75, recorded last December, and trade around $19. It was on this day last year, i.e. December 3, 2020, that ...
- Drug repurposing screening identified tropifexor as a SARS-CoV-2 papain-like protease inhibitor
Encouraging progress has been made in developing small molecule inhibitors targeting the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) and main protease (Mpro). However, the development of ...